Entecavir for Biological Agents Associated HBV Reactivation in Inflammatory Arthritis Patients

NCT01907230 ↗

Phase 4 Unknown 115 enrolled Taipei Veterans General Hospital, Taiwan

RandomizedParallel-groupOpen-labelPrevention

Summary

Antiviral prophylaxis can prevent the risk of biologic agents-associated HBV reactivation in hepatitis B inactive carriers and patients with past HBV infection

Timeline

Start: 2013-09-10
Primary completion: 2018-12-31
Completion: 2019-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Entecavir	Small molecule	0.5 mg	Oral

Entecavir for Biological Agents Associated HBV Reactivation in Inflammatory Arthritis Patients

Summary

Timeline

Drugs

Indications